Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research note released on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their price objective on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Price Performance

Shares of NASDAQ EVGN opened at $1.61 on Tuesday. Evogene has a 12 month low of $1.44 and a 12 month high of $10.40. The firm’s 50 day simple moving average is $2.25 and its 200-day simple moving average is $4.26. The stock has a market capitalization of $8.64 million, a price-to-earnings ratio of -0.36 and a beta of 1.43.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors and hedge funds.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.